Non-invasive surrogate markers of pulmonary hypertension are associated with poor survival in patients with cancer.

ABSTRACT:

Background

Cancer is one of the leading causes of death worldwide, and cardiopulmonary comorbidities may further adversely affect cancer prognosis. We recently described lung cancer-associated pulmonary hypertension (PH) as a new form of PH and comorbidity of lung cancer. While patients with lung cancer with PH had significantly reduced overall survival compared with patients without PH, the prevalence and impact of PH in other cancers remain unclear.

Methods

In this retrospective, observational cohort study, we analysed the prevalence and impact of PH on clinical outcomes in 1184 patients with solid tumours other than lung cancer, that is, colorectal, head and neck, urological, breast or central nervous system tumours, using surrogate markers for PH determined by CT.

Res

SUBMITTER: Cekay M 

PROVIDER: S-EPMC11344493 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature